MNPR רווח למניה בשנים עשר החודשים האחרונים Monopar Corp

Monopar Therapeutics (MNPR) has fully outsourced drug production to contract manufacturers to optimize costs. The TTM annual earnings per share on the GURU.Markets daily chart demonstrates financial stability, where -2.57 shows the current value of the metric. R&D efficiency allows for a lean staff of leading scientists, while growth potential is fueled by camsirubicin trials and the development of radiopharmaceuticals.

Professional issuer selection is based on an analysis of a business's ability to generate real income, with the efficiency of profit distribution among shareholders serving as the key filter. This 12-month net income per share history reflects the annual financial result of a single security, which for Monopar Therapeutics (MNPR), given its early-stage oncology drug development, indicates an investment phase and a lack of current operating revenue.